Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Biondvax Pharma Ads
(NQ:
BVXV
)
5.450
USD
-0.500 (-8.40%)
Streaming Delayed Price
Updated: 8:03 AM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Biondvax Pharma Ads
< Previous
1
2
3
Next >
BiondVax Announces Appointment of Amir Reichman as New CEO
January 21, 2021
Pharma Industry Veteran in Vaccines will Assume Role Full Time March 2, 2021, with Focus on Developing Product Pipeline in Infectious Diseases
From
PR Newswire
/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
October 23, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today...
From
PR Newswire
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate
October 23, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today...
From
PR Newswire
BiondVax Announces At-The-Market (ATM) Equity Offering Program
October 02, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an...
From
PR Newswire
BiondVax Announces Second Quarter 2020 Financial Results
August 20, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its...
From
PR Newswire
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
August 13, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of the...
From
PR Newswire
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
July 01, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax's M–001 universal influenza...
From
PR Newswire
BiondVax Announces First Quarter 2020 Financial Results
June 30, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its...
From
PR Newswire
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
June 12, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its...
From
PR Newswire
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
June 10, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate....
From
PR Newswire
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
May 20, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since January 1, 2020...
From
PR Newswire
BiondVax Announces Upcoming Expiration of Public Warrants
May 04, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on Nasdaq under the...
From
PR Newswire
Thinking about buying stock in Capricor Therapeutics, NXT-ID Inc, Brinker International, AMC Entertainment, or Biondvax Pharmaceuticals?
April 29, 2020
InvestorsObserver issues critical PriceWatch Alerts for CAPR, NXTD, EAT, AMC, and BVXV.
From
PR Newswire
New Directors Elected to BiondVax's Board of Directors
March 24, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company's Annual General Meeting...
From
PR Newswire
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
March 19, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Company's...
From
PR Newswire
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
February 05, 2020
Data published on Clinicaltrials.gov
From
PR Newswire
BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
January 16, 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced that...
From
PR Newswire
BiondVax Announces Third Quarter 2019 Financial Results and Business Update
November 26, 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its...
From
PR Newswire
Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
November 18, 2019
Results expected by end of 2020
From
PR Newswire
BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
October 07, 2019
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine...
From
PR Newswire
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
August 28, 2019
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced the...
From
PR Newswire
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
July 16, 2019
Funds to complete ongoing pivotal, clinical efficacy, Phase 3 trial of the M-001 Universal Flu Vaccine candidate and scale-up manufacturing
From
PR Newswire
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
July 08, 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine...
From
PR Newswire
European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million
June 26, 2019
The Board of Directors and Management of BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), was honored to host Mr. Ambroise Fayolle, Vice-President of the European Investment Bank (EIB), during his visit...
From
PR Newswire
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
June 18, 2019
Pivotal Clinical Efficacy Phase 3 Clinical Trial Results Expected in 2020
From
PR Newswire
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
June 10, 2019
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced a rights...
From
PR Newswire
BiondVax Announces First Quarter 2019 Financial Results
May 30, 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its...
From
PR Newswire
Kadimastem Announces Leadership Changes
May 29, 2019
Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef has stepped down as Chief Executive Officer. Rami Epstein has assumed the role of Chief Executive...
From
PR Newswire
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
May 13, 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition...
From
PR Newswire
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
April 30, 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently undergoing a pivotal clinical...
From
PR Newswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password
